The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48-Month Analysis
van Dyck et al
The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48-Month Analysis
